Table 2. Patient clinicopathological characteristics.
Clinicopathological feature | NO. (%) | |
Gender | male | 67 (59) |
female | 47 (41) | |
Age (years) | <60 | 72 (50) |
≥60 | 72 (50) | |
median (years) | 59 | |
Gastrointestinal bleeding | yes | 44 (39) |
no | 70 (61) | |
Primary tumor site | stomach | 73 (65) |
duodenum | 5 (4) | |
intestine | 24 (21) | |
colorectum | 7 (6) | |
intraperitoneally with unknown primary origin | 5 (4) | |
Tumor number | single | 110 (97) |
multiple | 4 (3) | |
Primary tumor size | >10 cm | 31 (27) |
5.1–10 cm | 44 (39) | |
0–5 cm | 39 (34) | |
Mitotic index (per 50 HPFs) | >10 | 11 (10) |
6–10 | 20 (18) | |
0–5 | 83 (72) | |
Surrounding tissue invasion | yes | 24 (21) |
no | 90 (79) | |
Tumor necrosis | yes | 67 (59) |
no | 47 (41) | |
Predominant cell type | spindle | 88 (77) |
epithelioid | 15 (13) | |
mixed | 11 (10) | |
Cellularity | high | 57 (50) |
moderate | 45 (39) | |
paucicellular | 12 (11) | |
Postoperative IM treatment | yes | 21 (18) |
no | 85 (75) | |
non-standard* | 8 (7) | |
AFIP-Miettinen criteria | very low risk | 30 (26) |
low risk | 23 (20) | |
moderate risk△ | 16 (14) | |
high risk▴ | 43 (38) | |
insufficient data | 2 (2) |
8 patients stopped IM treatment at mean of 2.2 months due to severe adverse effects;
one case with double tumors upstaged from low-risk;
two cases with double tumors upstaged from moderate-risk; IM, imatinib mesylate.